Clinical trials: Atopic Eczema/Dermatitis (Non-Specific)
Atopic Dermatitis, Atopic Dermatitis, Unspecified
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
- Trial name
- NCT06899204
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pfizer
Atopic Dermatitis, Atopic Dermatitis (AD)
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Patients
- Trial name
- NCT07448363
- Testing
- Abrocitinib, Upadacitinib, Baricitinib
- Where
- Costa Rica
- Volunteers
- 50 people
- Sponsor
- Caja Costarricense de Seguro Social
Atopic Dermatitis
Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?
It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards…
- Trial name
- NCT03142139
- Testing
- RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib, RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib, RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated
- Volunteers
- 1,027,559 people
- Sponsor
- Bandim Health Project
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Trial name
- NCT07205081
- Testing
- ATTO-3712
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Atopic Eczema/Dermatitis (Non-Specific)
Skin bioMARkers for Atopic Eczema Therapy Evaluation
The study aims to investigate two new non-invasive technologies for assessing skin properties to identify and validate a range of safety biomarkers that may be considered useful as primary outcome measures for evaluating the…
- Trial name
- SMART (NCT04194814)
- Testing
- crisaborole (2%) ointment, betamethasone valerate 0.1% cream
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust